Art. -Nr.: HY-B1455

Clindamycin

15 Cited Publications

Kundenbewertung

Based on 15 publication(s) in Google Scholar

Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.90%
CAS. Nr.: 18323-44-9
Formel: C₁₈H₃₃ClN₂O₅S
Molecular Weight:424.98

Speicherung:

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Clindamycin Chemical Structure

CAS. Nr.: 18323-44-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (15)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Plasmodium

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

Alle Parasite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
B-cell	IC₅₀	>400 μM Compound: Clindamycin	Antiproliferative activity against Theileria parva-induced proliferation of bovine B lymphocyte assessed as inhibition of [3H]thymidine uptake after 48 hrs Antiproliferative activity against Theileria parva-induced proliferation of bovine B lymphocyte assessed as inhibition of [3H]thymidine uptake after 48 hrs	[PMID: 19075064]
Erythrocyte	IC₅₀	>25 μM Compound: CLIN	Antimalarial activity against synchronous ring stage Plasmodium falciparum 3D7 infected in human Erythrocyte assessed as inhibition of parasite growth incubated for 96 hrs supplemented with IPP by [3H]-hypoxanthine incorporation assay Antimalarial activity against synchronous ring stage Plasmodium falciparum 3D7 infected in human Erythrocyte assessed as inhibition of parasite growth incubated for 96 hrs supplemented with IPP by [3H]-hypoxanthine incorporation assay	[PMID: 39241483]
HeLa	IC₅₀	>400 μg/mL Compound: Clindamycin	Antiproliferative effect against HeLa cells after 48 hrs Antiproliferative effect against HeLa cells after 48 hrs	[PMID: 17088489]
HeLa	IC₅₀	200 μg/mL Compound: Clindamycin	Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
MG-63	IC₅₀	>400 μg/mL Compound: Clindamycin	Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
MG-63	IC₅₀	250 μg/mL Compound: Clindamycin	Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs	[PMID: 17088489]
Osteoblast	IC₅₀	>400 μg/mL Compound: Clindamycin	Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs	[PMID: 17088489]
Osteoblast	IC₅₀	150 μg/mL Compound: Clindamycin	Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs	[PMID: 17088489]

In Vitro

Clindamycin (25 μg/mL, 1-18 h) inhibits ceftazidime (HY-B0593)-induced endotoxin release pretreatment in E. coli O55:B5^[3].
Clindamycin (50-100 μg/mL, 0-12 min) enhances antibody- and complement-dependent phagocytosis in Staphylococcus aureus^[4].
Clindamycin (0-500 μg/mL, 24-72 h) inhibits the cell proliferation in osteoblast cell culture model, stimulates the cell metabolism of osteoblast at the contratibution of 10 μg/mL^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:

THP-1 cells with stimulated E. coli O55:B5
Concentration:

3.13-50 μg/mL
Incubation Time:

1-18 h
Result:

Reduced TNF-α concentrations after pretreatment for 4 or 18 h at 25 and 50 μg/mL.

Cell Viability Assay^[5]

Cell Line:

Osteoblast cell culture model
Concentration:

0-500 μg/mL
Incubation Time:

24-72 h
Result:

Increased alkaline phosphatase (ALP)-activity at 10 μg/mL at 24 and 48 h.
Increased LDH values at 500 μg/mL at 24 and 48 h, indicating cytotoxicity.
Increased calcification at 10 and 25 μg/mL,decreased or no calcification was found at 50 μg/ml.

In Vivo

Clindamycin (50-300 mg/kg; i.v., p.o.) dosage doesn’t affect pharmacokinetic parameters in rats^[6].
Clindamycin (160-600 mg/kg; i.v.) improves survival in a dose-dependent manner in endotoxic shock mouse model^[7].
Clindamycin (17-50 mg/kg, i.v.) has good penetration into rat muscle tissue that can be applied to inhibit the main bacteria causing odontogenic infections^[8].
1.19
Pharmacokinetic Analysis in Rat Model^[8]

Route	Dose (mg/kg)	t_1/2 (h)	C_max (mg/mL)	T_max (h)a	AUC_0-inf (h.mg/L)	T
i.v.	51(Plasma)	2.51 (2.37-2.83)	35.21 (25.04-42.65)	0.08 ± 0.00	44.78 (28.82-65.65)	/
i.v.	51(Tissue)	2.82 (2.57-3.05)	14.20 (10.63-14.89)	0.25 ± 0.00	16.54 (13.83-18.35)	1.10
i.v.	17(Tissue)	3.25 (3.13-3.44)	4.82 (3.35-6.66	0.25 ± 0.00	/	/

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Endotoxic shock mouse model^[7]
Dosage:

160-600 mg/kg
Administration:

Intravenous injection (i.v.)
Result:

Decreased survival rates to 92 and 36% treated with 520- and 600-mg/kg doses.
Lowered the peak concentrations of tumor necrosis factor alpha (TNF-α) and interleukin-1β (IL-1β) in serum.
Increased the the peak concentrations of IL-6 in the sera.

Chemical Information

CAS. Nr. 18323-44-9
Appearance Solid
Molecular Weight 424.98
Formel C₁₈H₃₃ClN₂O₅S
Color White to light yellow
SMILES

CN(C[C@H](CCC)C1)[C@@H]1C(N[C@@]([C@@H](Cl)C)([H])[C@@]2([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (15)

All OthersBio/Physico-chemical AssayMicrobiological Assay

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Acta Pharm Sin B

Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2. [Abstract]

2021 Sep;11(9):2850-2858. PMID: 33723501
Water Res

Quantifying community-wide antibiotic usage via urban water fingerprinting: Focus on contrasting resource settings in South Africa. [Abstract]

2023 Jul 15:240:120110. PMID: 37247434

Clindamycin purchased from MedChemExpress. Usage Cited in: Water Res. 2023 Jul 15:240:120110. [Abstract]

It can be observed that both PNDIs and PNDPs for several AAs show clear seasonality with high usage in the wet (June-November) and low usage in the dry (December-May) season. This is especially pronounced in the case of sulfonamides and TMP-trimethoprim, macrolides (CLI-clindamycin and CLR-clarithromycin).
EBioMedicine

A novel inhibitor of monooxygenase reversed the activity of tetracyclines against tet(X3)/tet(X4)-positive bacteria. [Abstract]

2022 Apr;78:103943. PMID: 35306337

Clindamycin purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2022 Apr;78:103943. [Abstract]

Plumbagin, in combination with the nontetracycline antibiotics gentamycin, erythromycin, clindamycin or polymyxin E, had synergistic or additive effects on E. coli DH5α+pAM401-tet(X3).

Clindamycin purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2022 Apr;78:103943. [Abstract]

Plumbagin, in combination with the nontetracycline antibiotics gentamycin, erythromycin, clindamycin or polymyxin E, had synergistic or additive effects on E. coli DH5α+pAM401-tet(X4).
J Exp Med

Antibiotic use in early life impairs MAIT cell-mediated immunity in adulthood. [Abstract]

2026 Mar 2;223(3):e20241287. PMID: 41400657
ACS Environ Au

Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]

2025 Aug 5;5(6):573-582. PMID: 41277996

Clindamycin purchased from MedChemExpress. Usage Cited in: ACS Environ Au. 2025 Aug 5;5(6):573-582. [Abstract]

SulfurFinder and molecular networking were leveraged to putatively annotate feature #3482 as pirlimycin, which is structurally related to clindamycin with a modified cosine score of 0.83.
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576
ACS Omega

Lapatinib Acts against Biofilm Formation and the Hemolytic Activity of Staphylococcus aureus. [Abstract]

2022 Mar 3;7(10):9004-9014. PMID: 35309438
Microbiol Spectr

Montelukast treats Streptococcus pneumoniae-induced sepsis via antibacterial and anti-inflammatory activities. [Abstract]

2025 Oct 15:e0122125. PMID: 41090944

Clindamycin purchased from MedChemExpress. Usage Cited in: Microbiol Spectr. 2025 Oct 15:e0122125. [Abstract]

Combinations with clindamycin (CLI) and azithromycin (AZM) showed limited or strain-dependent synergy, with most FICI values near or above 0.5.
Dermatol Clin

2024 September 12.
Future Microbiol

Synergistic drug strategy against mastitis-associated MRSA strains. [Abstract]

2025 Oct 13:1-10. PMID: 41082411
Diagn Microbiol Infect Dis

A rapid bacterial labeling method for phenotypic antimicrobial susceptibility testing. [Abstract]

2026 Feb;114(2):117181. PMID: 41205476
bioRxiv

Exposure to Antibiotics Modifies the Immune Profiles of Bacterial Extracellular Vesicles from Common Vaginal Anaerobes. [Abstract]

2026 May 22:2026.05.21.726874. PMID: 42239425
bioRxiv

2024 May 10.
bioRxiv

2024 Jan 18.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 116.67 mg/mL (274.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 2 mg/mL (4.71 mM; ultrasonic and warming and heat to 60°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3531 mL

11.7653 mL

23.5305 mL

5 mM

0.4706 mL

2.3531 mL

4.7061 mL

10 mM

0.2353 mL

1.1765 mL

2.3531 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Hodille E, et al. Clindamycin suppresses virulence expression in inducible clindamycin-resistant Staphylococcus aureus strains. Ann Clin Microbiol Antimicrob. 2018 Oct 20;17(1):38. [Content Brief]

[2]. Kremsner PG. Clindamycin in malaria treatment. J Antimicrob Chemother. 1990 Jan;25(1):9-14. [Content Brief]

[3]. Kishi K, et al. Clindamycin suppresses endotoxin released by ceftazidime-treated Escherichia coli O55:B5 and subsequent production of tumor necrosis factor alpha and interleukin-1 beta. Antimicrob Agents Chemother. 1999 Mar;43(3):616-22. [Content Brief]

[4]. Veringa EM, et al. Clindamycin at subinhibitory concentrations enhances antibody- and complement-dependent phagocytosis by human polymorphonuclear leukocytes of Staphylococcus aureus. Chemotherapy. 1987;33(4):243-9. [Content Brief]

[5]. Naal FD, et al. The effects of clindamycin on human osteoblasts in vitro. Arch Orthop Trauma Surg. 2008 Mar;128(3):317-23. [Content Brief]

[6]. Yang SH, Lee MG. Dose-independent pharmacokinetics of clindamycin after intravenous and oral administration to rats: contribution of gastric first-pass effect to low bioavailability. Int J Pharm. 2007 Mar 6;332(1-2):17-23. [Content Brief]

[7]. Hirata N, et al. Pretreatment of mice with clindamycin improves survival of endotoxic shock by modulating the release of inflammatory cytokines. Antimicrob Agents Chemother. 2001 Sep;45(9):2638-42. [Content Brief]

[8]. Faggion PI, et al. Is the penetration of clindamycin into the masseter muscle really enough to treat odontogenic infections? Clin Oral Investig. 2021 May;25(5):3257-3266. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	2.3531 mL	11.7653 mL	23.5305 mL	58.8263 mL
DMSO	5 mM	0.4706 mL	2.3531 mL	4.7061 mL	11.7653 mL
	10 mM	0.2353 mL	1.1765 mL	2.3531 mL	5.8826 mL
	15 mM	0.1569 mL	0.7844 mL	1.5687 mL	3.9218 mL
	20 mM	0.1177 mL	0.5883 mL	1.1765 mL	2.9413 mL
	25 mM	0.0941 mL	0.4706 mL	0.9412 mL	2.3531 mL
	30 mM	0.0784 mL	0.3922 mL	0.7844 mL	1.9609 mL
	40 mM	0.0588 mL	0.2941 mL	0.5883 mL	1.4707 mL
	50 mM	0.0471 mL	0.2353 mL	0.4706 mL	1.1765 mL
	60 mM	0.0392 mL	0.1961 mL	0.3922 mL	0.9804 mL
	80 mM	0.0294 mL	0.1471 mL	0.2941 mL	0.7353 mL
	100 mM	0.0235 mL	0.1177 mL	0.2353 mL	0.5883 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Clindamycin

15 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Clindamycin

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Antibacterial Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Antiparasitic Compound library

Rare Diseases Drug Library

Pediatric Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Anti-Drug-Resistant Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product-like Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Clindamycin

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Alle Parasite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (15)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Clindamycin Related Classifications

HY-B1455 Related Classifications